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Loss of epithelial barrier integrity is considered an early step in the pathogenesis of Crohn’s disease (CD), and the 
rate of enterocyte apoptosis is one of the determinants of the intestinal barrier function. Tumor necrosis factor-α 
(TNF-α), one of the major proinflammatory mediators in CD, is one of the extrinsic signals which initiate apop-
tosis of enterocytes. The aim of this study was to investigate the early effects of experimental colitis on enterocyte 
apoptosis, and the effects of two anti-TNF treatments, infliximab (IFX) and etanercept (ETC). In addition, the 
importance of receptor I for TNF was tested in TNFR-1-/- mice.  
Circulating TNF-α levels were effectively reduced by IFX and ETC (p<0.01, both) at 3 and 6 h. Apoptosis of the 
ileal enterocytes, assessed by TUNEL staining, staining for Fas-ligand, and bax, increased at 3 and 6h. These al-
terations were prevented by both anti-TNF strategies, and in TNFR-1-/- animals. The anti-apoptotic protein Bcl-2 
was expressed in the ileal epithelium under control conditions, but was suppressed in DNB-colitis. Expression of 
Bcl-2 was maintained in both anti-TNF treatments and TNFR-1-/- mice. 
DNB colitis induced a very early, rapid increase of enterocyte apoptosis. Both anti-TNF strategies, IFX and ETC, 
were equally effective in suppressing enterocyte apoptosis, most likely by inactivation of circulating TNF-α. 
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INTRODUCTION 
A defect of the gastrointestinal barrier function 
can be considered an important stage in the patho-
genesis of Crohn’s disease (CD), leading to increased 
penetration of luminal antigens in the gut wall, thus 
initiating a self-perpetuating immune response. 
Whereas most research in the past few years has 
focused on the apical junctional complex between en-
terocytes [for review see ref 1-3], little attention has 
been given to the programmed cell death of entero-
cytes, i.e. apoptosis. Under normal conditions, epithe-
lial cell shedding does not contribute to an alteration 
o f  t h e  i n t e s t i n a l  b a r r i e r  [ 4 ] ,  b u t  a n  i n c r e a s e  o f  t h e  
apoptotic rate may generate leaks contributing to a 
decrease in barrier function. It has been shown that 
tumor necrosis factor-α (TNF-α)-induced apoptosis 
contributes significantly to the loss of ions and water, 
and to the passage of small antigens [5].  
In CD, an imbalance of apoptosis is reported, 
characterized by prolonged survival of lamina propria 
proinflammatory cells [6,7] together with a shortened 
survival of the epithelial cell lining [8]. With the recent 
introduction of biologic therapies, it has been shown 
that Infliximab, a chimeric mouse/human IgG1 anti-
body against TNF-α, normalizes apoptotic rates by 
increasing T-cell death [9] and decreasing epithelial 
cell apoptosis [5,10]. However, most research has 
concentrated on the regulatory effect of Infliximab 
(IFX), or its fully human analog adalimumab (ADA), 
on apoptosis of proinflammatory cells, such as 
monocytic cell lines and lamina propria T-cells, and 
this effect has been explained by the direct interaction 
of these antibodies with membrane-bound TNF. 
Etanercept (ETC), a synthetic fusion protein of a re-
combinant human TNF receptor subunit with a hu-
man IgG1, failed to show clinical efficacy [11] and Int. J. Med. Sci. 2008, 5 
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appeared to be less effective at inducing apoptosis of 
peripheral blood monocytes and of lamina propria 
derived T-cells [12,13], although some activity in 
cell-dependent cytotoxicity and antibody-dependent 
cell-mediated cytoxicity has been reported recently 
[14]. Finally, some doubt about the importance of the 
pro-apotptotic effect in the mediation of clinical effi-
cacy has been added recently after positive clinical 
studies with certolizumab, a pegylated humanized 
Fab’ fragment of an IgG4 [15]. 
Since no information on the epithelial effects of 
the anti-TNF strategy is yet available, we designed the 
present study to investigate the very early effects of 
experimental colitis on ileal enterocyte apoptosis, in-
duced by dinitrobenzenesulphonic acid (DNB), a 
model which is very close to the classical Th-1 model 
employing trinitrobenzenesulphonic acid (TNB). In 
this model, we have previously shown that both IFX 
and ETC, prevent alterations of enterocyte tight junc-
tions [16]. In the present setting, we studied the effects 
of experimental colitis on ileal enterocyte apoptosis by 
means of TUNEL staining, immunohistochemistry for 
Fas-Ligand, the expression and immunostaining of 
bax and the anti-apoptotic protein bcl-2, and the ef-
fects of TNF-blockade by IFX and ETC. In an addi-
tional experiment, the results were compared to the 
effects of DNB colitis in knockout (k.o.) mice for the 
receptor I of TNF-α (TNFR-1-/-).  
MATERIALS AND METHODS 
All experiments were carried out in accordance 
with the national law on animal protection. Experi-
mental protocols were approved by the Ethics Com-
mittee of the University of Messina. Male CD mice 
(Harlan, Italy) were housed for two weeks under 
standard conditions, with free access to tap water and 
standard lab chow. Colitis was induced by intrarectal 
administration of 5 mg of dinitrobenzenesulphonic 
acid (DNB) dissolved in 50% ethanol under light ether 
anesthesia. Control colitis was induced by intrarectal 
instillation of 50% ethanol only. Twenty-five mice per 
group were sacrificed at 3 and 6 hours after colitis 
induction. Blood was drawn by intracardiac puncture 
under ether anaesthesia, the abdomen was opened by 
a midline incision and the entire colon was removed, 
opened and macroscopic damage score determined 
[17]. Subsequently, the distal colon and terminal ileum 
were cut in longitudinal slices and fixed in buffered 
formalin.  
In a second experiment, mice were treated one 
hour before colitis induction with Infliximab (IFX; 
Schering-Plough, Milan; Italy; 5 mg/kg i.p.) or with 
Etanercept (ETC; Wyeth, Milan; Italy; 5 mg/kg s.c.). In 
parallel, mice subjected to anti-TNF treatment with 
sham colitis and colitis with sham treatment served as 
controls with an identical protocol as above. Both 
treatments have been shown to effectively antagonize 
TNF effects in vivo in mice [18,19]. 
In a third experimental setting, in mice lacking 
the TNF membrane receptor I (TNFR-1-/-, Jackson 
Laboratory, Bar Harbor, MN; USA) colitis was in-
duced as above and animals were sacrificed at 3 and 6 
h.  
Serum TNF-α determination 
Blood was spun and serum stored at -80°C, until 
analysis. Serum concentrations of TNF-α were deter-
mined by ELISA (Euroclone, Devon; UK). 
Histologic evaluation 
After fixation for 1 week at room temperature in 
buffered formaldehyde solution (10% in phosphate 
buffered saline), samples were dehydrated in graded 
ethanol and embedded in paraplast (Sherwood 
Medical, Mahwah, NJ; USA). Thereafter, 7 μm sections 
were deparaffinized with xylene, stained hematoxy-
lin/eosin, observed with a Axostar Plus equipped 
with AxioCam MRc (Zeiss, Milan, Italy) and studied 
using an Imaging computer program (AxioVision, 
Zeiss, Milan, Italy). 
Immunohistochemical assessment of apoptosis.  
After deparaffinization, slices were treated with 
protease (type XIV, Sigma) (2 mg/ml) for 10 min at 
37°C. Endogenous peroxidase was quenched with 
0.3% (v/v) hydrogen peroxide in 60% (v/v) methanol 
for 30 min. Non-specific adsorption was minimized by 
incubating the section in 2% (v/v) normal goat serum 
in PBS for 20 min. Endogenous biotin or avidin bind-
ing sites were blocked by sequential incubation for 15 
min with biotin and avidin (DBA, Milan, Italy), re-
spectively. Sections were incubated overnight with 1) 
polyclonal rabbit anti-Bcl-2 antibody (1:200 in PBS, 
w/v), 2) anti-bax (1:200, w/v) (anti-Bcl-2 and –bax 
antibodies, Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA; USA), or 3) anti-Fas-L (1:50, 
w/v)(Novocastra Lab Ltd, Newcastle upon Tyne, UK). 
Sections were washed with PBS, and incubated with 
secondary antibody obtained from Jackson Immuno 
Research, Laboratories, INC (Jackson San Francisco, 
CA, USA).,Specific labeling was detected with a bio-
tin-conjugated goat anti-rabbit IgG and avidin-biotin 
peroxidase complex (DBA, Milan, Italy). The counter 
stain was carried out with nuclear fast red (red back-
ground). All sections were observed using light mi-
croscopy (Axostar Plus equipped with AxioCam MRc, 
Zeiss, Milan, Italy) and studied using an Imaging 




UTP End Labelling (TUNEL) Assay.  
 TUNEL assay was conducted by using a TUNEL 
detection kit according to the manufacturer’s instruc-
tion (Apotag, HRP kit, Chemicon International, Milan, 
Italy). Briefly, sections were incubated with 20 μg/ml 
proteinase K for 15 min at room temperature and then 
washed with PBS. Endogenous peroxidase was inac-
tivated by 3% H2O2 for 30 min at room temperature 
and then washed with PBS. Sections were incubated 
with Working Strength TdT Enzyme in a humid at-
mosphere at 37°C for 60 min, and then washed with 
stop wash buffer. The sections were incubated at room 
temperature for 30 min with 
anti-digoxigenin-peroxidase and the signals were 
visualized with diaminobenzidine. Sections were 
counterstained with methyl-green (green background) 
(Vector Lab, Milan; Italy). 
Total protein extraction and Western blot analysis  
Tissue samples from the terminal ileum were 
homogenized with an Ultra-turrax T8 homogenizer in 
a buffer containing 20mM HEPES pH 7.9, 1.5mM 
MgCl2, 400 mM NaCl, 1 mM ethylenediamine-
tetraacetic acid (EDTA), 1 mM ethyleneglycoltetraace-
tic acid (EGTA), 1 mM dithiothreitol (DTT), 0.5 mM 
phenylmethylsulphonyl  fluoride (PMSF), 1.5 μg/ml 
trypsin inhibitor, 3 μg/ml pepstatin, 2 μg/ml leu-
peptin, 40 μM benzidamin, 1% NP-40, 20% glycerol. 
The homogenates were centrifuged (13000 rpm, 15 
min, 4°C); the surnatant was collected to evaluate 
contents. 
Protein concentration was determined with the 
Bio-Rad protein assay kit. Proteins were mixed with 
gel loading buffer; (50 mM Tris, 10% (w/v) sodium 
dodecyl sulphate (SDS), 10% (w/v) glycerol, 10% 
(v/v) 2-mercaptoethanol, 2 mg/ml bromophenol), 
boiled for 5 min and centrifuged at 10000 rpm for a 
few seconds. Protein concentration was determined 
and equivalent amounts (50 μg) of each sample elec-
trophoresed in a 12% (w/v) discontinuous poly-
acrylamide minigel. Proteins were separated electro-
phoretically and transferred to nitrocellulose mem-
branes. For immunoblotting, membranes were 
blocked with 5% non-fat dry milk in Tris-buffered 
saline (TBS) for 1 h and then incubated with primary 
antibodies against Bcl-2 (1:100), bax (1:100), and 
β-actin (1:5000) (Santa Cruz Biotechnology, CA; USA) 
over-night at 4°C. The membranes were washed three 
times for 10 min in TBS with 0.1% Tween 20 and in-
cubated with AffiniPure Goat Anti-Rabbit IgG cou-
pled to peroxidase (1:5000). The immune complexes 
were visualized using the SuperSignal West Pico 
chemiluminescence Substrate (PIERCE, USA). 
Data presentation and statistics 
Data of circulating TNF concentrations, macro-
scopic damage score, and densitometric units (West-
ern-blot) are given as mean values ± SEM; comparison 
was made with the Mann-Whitney test and Bon-
ferroni’s correction; a p value <0.025 was considered 
significant. 
RESULTS 
Macroscopic damage score (Table 1) and serum 
TNF-α (Table 2) are effectively reduced by 
anti-TNF treatment 
DNBS colitis led to high circulating TNF-α levels 
at 3 and 6 hours post-induction, which were effec-
tively reduced by IFX at 3h and 6 h (p<0.01, both) 
compared with untreated colitis, and only at 6 h by 
ETC (p<0.01). Macroscopic damage score was similar 
in all groups at 3h, but significantly (p<0.05) reduced 
in both treatment groups at 6 h compared to untreated 
colitis. At both time-points k.o. mice for TNFR-1 had a 
similar damage score to untreated animals. 
Table 1: macroscopic damage score 3 h and 6 h after colitis 
induction in untreated colitis (DNBS), colitis treated with IFX 5 
mg/kg i.p. (DNBS + IFX), in colitis treated with ETC 5 mg/kg 
s.c., and in TNFR1 k.o. mice (TNFR
-/-); * p<0.05 vs corre-
sponding untreated colitis; unpaired t-test. 
  Macroscopic damage score 
  3 hours  6 hours 
DNBS 
(n = 25) 
1.4 ± 0.2  2.2 ± 0.3 
DNBS + IFX 
(n = 25) 
1.2 ± 0.2   1.1 ± 0.4 * 
DNBS + ETC 
(n = 25) 
1.9 ± 0.4   0.9 ± 0.4 * 
TNFR-/- 
(n = 25) 
0.8 ± 0.1  1.4 ± 0.4 
 
Table 2: serum TNF-alpha concentrations at 3 h and 6 h in 
untreated colitis (DNBS), colitis treated with IFX 5 mg/kg i.p. 
(DNBS + IFX), and in colitis treated with ETC 5 mg/kg s.c.; * 
p<0.01 vs corresponding untreated colitis; unpaired t-test. 
  Serum TNF-alpha; pg/ml 
  3 hours   6 hours 
DNBS 
(n = 25) 
 149 ± 8   100 ± 2 
DNBS + IFX 
(n = 25) 
 42 ± 2 *   67 ± 6 * 
DNBS + ETC 
(n = 25) 
 110 ± 9 
 
 39 ± 9 * 
 
Enterocyte apoptosis in experimental colitis and 
effects of TNF- inhibition and lack of TNFR-1 
Isolated positivity was observed at any 
time-point in control ilea on TUNEL staining (fig.1), 
nor in sham colitis treated with ETC or IFX. Three 
hours after colitis induction a few cells distributed 
along the entire length of the villi stained positive (fig. Int. J. Med. Sci. 2008, 5 
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1 C). At 6 h, the number of apoptotic cells had in-
creased (fig. 1 D). No TUNEL-positive cells were ob-
served at either time-points with either treatment, ETC 




Fig. 1: Tunel staining at 3 h (left column) at 6 h 
(right column) in control ilea (A,B) showing no 
positivity except for isolated enterocytes at both 
time-points; positivity (arrowheads) appeared 3 h 
(B) after colitis induction with DNB/ethanol 
along the villus axis and increased at 6 h (C); 
positivity of Tunel staining was completely pre-
vented by treatment with ETC (5 mg/kg s.c.) (E,F) 
and with IFX (G,H), and in TNFR-1
-/- mice (I,J). 
 
Fas-L (fig 2) was not detectable under 
control conditions in the ileal mucosa. 
Three and 6 hours after colitis induction, 
enterocyte nuclei and cytoplasm stained 
positive in the two upper thirds of the villi, 
whereas the lower third remained nega-
tive (fig. 2 B,C). Expression of Fas-L was 
absent at both time-points in colitis treated 
with ETC or IFX (fig. 2 E-H), and in 
TNFR-1-/- mice (fig. 2 I,J). 
Like Fas-L, bax was also not detect-
able in controls (fig 3 A,B), but was in-
creased in animals with colitis (fig. 3 C,D), 
especially in the crypt compartment. 
Treatment with ETC (fig 3 E,F) and with 
IFX (fig. 3 G,H) and the absence of the re-
ceptor-1 for TNF-α (fig. 3 I,J) prevented the 
expression of bax in the ileal enterocytes. 
On Western-blot analysis (fig. 4) bax was 
expressed strongly in the ileal mucosa of 
animals with colitis at 3 and 6h. This in-
creased expression was effectively pre-
vented by both IFX and ETC. In TNFR-1-/- 
mice with colitis, some expression of bax 
in the subepithelial layer was present.  
Expression of the anti-apoptotic pro-
tein bcl-2 (fig. 5) was evident under control 
conditions in the upper ¾ of ileal villi (fig. 
5 A,B). Expression of bcl-2 was completely 
abolished in mice with experimental coli-
tis, at both time-points (fig. 5 C,D). Both 
treatments, ETC and IFX, prevented the 
loss of bcl-2 at 3 and 6 h (fig. 5 E-H). Simi-
larly, in TNFR-1-/- mice, bcl-2 was pre-
served at both time-points (fig. 5 I,J). 
On Western-blot analysis, protein concentration 
of bcl-2 (fig. 6) was significantly reduced (p<0.01 or 
less) in mice with colitis compared to untreated sham 
colitis or sham colitis treated with IFX or ETC, but was 
preserved in mice with colitis, by either treatment, IFX 
and ETC, at 3 and 6 hours. 
 
 




Fig. 2: Immunostaining for Fas-L showed its absence under 
control conditions in the ileal mucosa (A,B). Three (C) and 6 
hours (D) after colitis induction with DNB/ethanol, enterocyte 
nuclei and cytoplasm stained positive in the two upper thirds 
along the villi (arrowheads) (the rectangle indicate an area 
where almost all entercytes stained positive for Fas-L), 
whereas the lower third remained negative. Both treatments, 
ETC (5 mg/kg s.c.) (E,F) and IFX (5 mg/kg i.p.) (G,H), pre-
vented positivity for Fas-L, as well as the absence of the re-
ceptor 1 for TNF-α (I,J). 




Fig. 3: Immunostaining for bax showed its absence under control conditions in the ileal mucosa (A,B). Three (C) and 6 hours (D) 
after colitis induction with DNB/ethanol, enterocyte nuclei and cytoplasm stained positive in the two upper thirds along the villi 
(arrowheads) and the crypt compartment (a short segment is highlighted within brackets). Both treatments, ETC (5 mg/kg s.c.) (E,F) 




Fig. 4: Western-blot analysis of ileal concentrations of bax three hours (a; upper panel) and 6 hours (b; lower panel) in control 
animals with sham colitis (sham WT), in control TNFR-1
-/- animals and sham colitis (sham TNF-α KO), in animals treated with ETC 
or IFX alone without colitis, in animals with DNBS/ethanol colitis and sham treatment (DNBS WT), in TNFR-1
-/- animals with 
colitis (DNBS TNF-α KO), and in animals with colitis and ETC or IFX treatment; protein expression of bax was significantly in-
creased in DNBS colitis compared with all other conditions. At 6 h in TNFR-1
-/- animals with colitis traces of bax were detectable. 




Fig. 5: Expression of the anti-apoptotic protein Bcl-2 was evi-
dent under control conditions in the upper ¾ of ileal villi (ar-
rowheads) (A,B), but was completely abolished by experi-
mental colitis at both time-points (C,D). Both treatments, ETC 
(5 mg/kg s.c.) (E,F) and IFX (5 mg/kg i.p.) (G,H), prevented the 
loss of bcl-2; immunohistologic expression of the 
anti-apoptotic protein Bcl-2 was not altered in TNFR-1
-/- mice 
after induction of colitis with DNB/ethanol at 3 (I) and 6 hours 




Fig. 6: Western-blot analysis of ileal concentrations of Bcl-2 three hours (a; upper panel) and 6 hours (b; lower panel) in control 
animals with sham colitis (sham WT), in control TNFR-1
-/- animals and sham colitis (sham TNF-α KO), in animals treated with ETC 
or IFX alone without colitis, in animals with DNBS/ethanol colitis and sham treatment (DNBS WT), in TNFR-1
-/- animals with 
colitis (DNBS TNF-α KO), and in animals with colitis and ETC or IFX treatment; protein expression of Bcl-2 was significantly 
reduced in DNBS colitis compared with all other conditions.  
 
DISCUSSION 
In the present experiment, the short term effects 
of DNB colitis on apoptosis of the ileal enterocytes 
have been shown for the first time in a whole organ-
ism, thus underlining the evidence that this model 
may be used to study inflammation-associated effects 
on programmed cell death of enterocytes. Addition-
ally, we have demonstrated that both anti-TNF treat-
ments, ETC and IFX, were equally effective in abol-
ishing colitis-induced enterocyte apoptosis, and we 
confirmed that the proapoptotic effect is mediated 
through receptor 1 for TNF- α. Int. J. Med. Sci. 2008, 5 
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At present, few studies have addressed the effect 
of TNF-α in vivo on epithelial cell apoptosis [20] and 
its role in chronic inflammatory bowel diseases (IBD), 
especially in non-inflamed gut segments. Most re-
search has focused on actively inflamed mucosa in 
experimental models [21] as well as in human disease 
[5,10,22]. In a very recent paper, an upregulation of 
TNF-related apoptosis-inducing ligand (TRAIL), a 
membrane-bound protein with a very close homology 
to TNF-α and FasL, has been found on enterocytes of 
actively inflamed mucosa of patients with IBD[23]. 
TRAIL thus represents an additional pro-apoptotic 
mechanism in IBD. In the present paper, for the first 
time we show that epithelial cell apoptosis increased 
distantly from actively inflamed mucosa in this model 
of experimental colitis. Similar effects on enterocyte 
apoptosis have been described in models of experi-
mental liver failure associated with high circulating 
TNF-α levels [24].  
The interrelation between apoptosis and loss of 
barrier function has been addressed in some previous 
studies [25] concluding that the physiologic event does 
not lead to permeability defects, whereas apoptosis 
induced by exposure to cytokines such as TNF-α was 
found recently to disrupt barrier function in terms of 
epithelial conductivity [5]. From studies in several cell 
lines it appears that IFN-γ or TNF-α sensitize cells to 
Fas-mediated apoptosis [26,27].  
In our study, enterocyte apoptosis was com-
pletely prevented by both anti-TNF treatments, and in 
TNFR-1-/- mice, together with a preserved expression 
of anti-apoptotic protein Bcl-2. Our findings agree 
both with a recent paper by Zeissig and coll [10] who 
investigated the effects of IFX treatment in vivo on 
colonic mucosa in CD patients showing a significant 
reduction of epithelial cell apoptosis, and with Marini 
et al [21] in Samp/YitFc mice, a murine model with 
spontaneous ileitis resembling human CD very 
closely, where the administration of a chimeric 
rat/mouse anti-TNF-α antibody reduced epithelial 
apoptosis in the inflamed ileum. 
The nature of available anti-TNF strategies, ETC, 
onercept, IFX, and ADA is different. ETC and onercept 
are genetically engineered fusion proteins consisting 
of two molecules of the natural p75 or p55 TNF re-
ceptors and the Fc domain of human IgG1, whereas 
IFX and ADA are IgG1 antibodies against TNF-α, the 
former a chimeric mouse/human IgG1 antibody, the 
latter a fully human IgG1-antibody. The affinity of all 
these molecules is extremely high for circulating 
TNF-α; however, membrane-bound TNF is not, or 
less, recognized by ETC [28], whereas IFX and ADA 
also bind to this uncleaved form. This different TNF 
binding pattern may explain the distinct therapeutic 
effects of these anti–TNF drugs. Indeed, studies in 
Crohn’s disease patients were disappointing with ETC 
[11], whereas the efficacy of IFX and ADA have been 
well documented. 
A very important aspect is the ability of IFX, as 
w e l l  a s  o f  A D A ,  n o t  o n l y  t o  b i n d  b o t h  s o l u b l e  a n d  
membrane-bound TNF but also to induce apoptosis of 
TNF-expressing cells. It has been shown that lamina 
propria T-cells survive too long in Crohn’s disease 
[29]. This increased survival of pro-inflammatory cells 
is associated with the perpetuation of inflammatory 
stimuli and an increased production of proinflamma-
tory cytokines, such as TNF-α. IFX induces apoptosis 
of peripheral blood monocytes from healthy volun-
teers and patients with CD dose-dependently by acti-
vation of caspase-8, 9 and 3 in a Fas-independent 
manner [30]. This effect has also been shown for ADA 
but not for ETC [13]. Subsequently, it was shown that 
IFX [9], but not ETC [12], induces apoptosis of lamina 
propria T cells in vivo and in a CD3/CD28-activated 
T-cell line. The pro-apoptotic effect of IFX was also 
shown by DiSabatino et al. [31] in vitro on lamina pro-
pria T cells and peripheral blood T cells from CD pa-
tients.  
Beyond this important difference between ETC 
and IFX, other discrepancies have been described, e.g. 
the response of peripheral T cells, in terms of cytokine 
production (TNF-α, interleukin-4, and interferon-γ) to 
non-specific and antigen specific stimulation in pa-
tients with AS, is downregulated during IFX treatment 
but increased by ETC [32,33]. In vitro, the opposite 
effect was not confirmed on intestinal T cells from CD 
patients, but there was a fourfold reduction of efficacy 
of ETC compared to IFX [14, 34]. 
As shown in our present study, ETC and IFX 
were equally effective in abolishing the coli-
tis-associated increase of ileal enterocytes and in the 
preservation of bcl-2 expression, suggesting an exclu-
sive effect of circulating and not membrane-bound 
TNF-α. Moreover, the same results were achieved us-
ing k.o. mice for TNFR-1, confirming the mediation of 
propapototic stimuli through this receptor [35]. Inter-
estingly, knock out mice for TNFR-1 showed a higher 
mortality in TNBS induced colitis [36], whereas those 
who lacked TNFR-2 developed a less severe disease 
despite higher serum TNF-α levels. This may be ex-
plained by secondary defence mechanisms mediated 
by TNFR-1. 
In conclusion, induction of enterocyte apoptosis 
represents a very early response of the ileum mucosa 
to distal colitis induced by DNBS, emphasizing the 
highly dynamic aspect of programmed cell death. This 
effect was most likely mediated by circulating TNF-α 
since its inhibition or the lack of TNFR-1 completely Int. J. Med. Sci. 2008, 5 
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prevented epithelial apoptosis. The upregulation of 
enterocyte apoptosis may represent a mucosal defence 
mechanism but, shooting down intestinal barrier 
function, the influx of antigens may be enhanced, in-
ducing local inflammatory response in genetic sus-
ceptible organisms.  
Our results show that intestinal segments distant 
from inflammation are highly sensitive, in terms of 
apoptosis and TJ protein expression/redistribution. In 
this context, it seems more likely that barrier dysfunc-
tion is a secondary event to inflammation. 
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